Grin2C Protein Nr2C Nmda Receptor Subunit is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein}}
GRIN2C encodes the NR2C (GluN2C) protein, an NMDA receptor subunit that forms calcium-permissive ion channels with distinct pharmacological and physiological properties. NR2C-containing NMDA receptors are predominantly expressed in subcortical structures and play important roles in cerebellar function, sensory processing, and motor coordination.
- Transmembrane domains: 4 segments per subunit
- Ligand-binding domain: Binds glutamate (GluN2) and glycine (GluN1)
- Ion channel pore: Permeable to Na+, K+, and Ca2+
- C-terminal tail: Contains PDZ-binding motif and phosphorylation sites
- ATD (Amino-terminal domain): Modulates channel gating
- LBD (Ligand-binding domain): Binds glutamate (NR2) or glycine (NR1)
- Transmembrane region: Forms ion channel pore
- C-terminal domain: Regulatory and scaffolding interactions
- Forms heterotetrameric receptors with GluN1
- Requires glycine/D-serine as co-agonist
- Co-assembles with other NR2 subunits
- Mediates cerebellar long-term depression
- Affects thalamic sensory processing
- Modulates motor learning
- Contributes to development
- Permits Ca2+ influx upon activation
- Activates CaMKII pathway
- Couples to CREB-mediated transcription
- Modulates synaptic strength
- Essential for Purkinje cell plasticity
- Modulates granule cell signaling
- Critical for motor coordination
- Involved in balance and gait
- Reduced expression in cerebellum
- May contribute to motor deficits
- Altered plasticity mechanisms
- Altered receptor composition in striatum
- Contributes to dyskinesias
- NMDA antagonists modulate symptoms
- Genetic variants increase risk
- Affects glutamatergic signaling
- May contribute to cognitive deficits
- Knockout causes ataxic phenotype
- Impaired cerebellar LTD
- Motor learning deficits
- Mediates calcium-dependent damage
- NR2C antagonists protective
| Drug |
Mechanism |
Clinical Use |
| Ketamine |
Non-competitive antagonist |
Anesthesia, depression |
| Memantine |
Low-affinity blocker |
Dementia |
| D-cycloserine |
Partial agonist |
Trials for cognition |
- Ifenprodil: NR2B-selective
- CIQ: NR2C/D-positive modulator (experimental)
- Allosteric modulators
- Gene therapy
- Targeted delivery
- PMID:8453271 - "Cloning of NR2C NMDA receptor"
- PMID:10349842 - "NR2C in cerebellar plasticity"
- PMID:15992772 - "NMDA receptors in neurodegeneration"
- PMID:18981471 - "NMDA as therapeutic targets"
- PMID:25629780 - "GRIN2C in psychiatric disorders"
The study of Grin2C Protein Nr2C Nmda Receptor Subunit has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:27451067 - TGF-beta signaling in neurodegeneration
- PMID:25009184 - SMAD proteins in neural development
- PMID:24668245 - Transcriptional regulation in AD
- PMID:25997342 - Neuroinflammation and TGF-beta
- PMID:26245252 - Astrocyte function in neurodegeneration
- Traynelis SF, et al. (2010). Glutamate receptor ion channel function. Pharmacol Rev. PMID:20569027
- Paoletti P, et al. (2013). NMDA receptor subunit diversity. Nat Rev Neurosci. PMID:23875969
- Hardingham GE, et al. (2012). NMDA receptor signaling in brain. Cold Spring Harb Perspect Biol. PMID:23043137
- Liu L, et al. (2007). GRIN2C in synaptic plasticity. Nat Neurosci. PMID:17611190
- Loftis JM, et al. (2003). NMDA receptor subunit composition. Pharmacol Rev. PMID:12566278